DocumentsDate added
Original article
Anzar Ashraf1,Anita Chakravarti2,Priyamvada Roy2,Oves Siddiqui2,Shipra Goel2,Neeru Kapoor2,Premashish Kar3
1 Virology laboratory, Department of Microbiology, Maulana Azad Medical College, Delhi-110002, India
2 Department of Microbiology, Maulana Azad Medical College, Delhi-110002, India
3 Department of Medicine, Maulana Azad Medical College & Associated Lok Nayak Hospital, Delhi-110002, India
Address reprint requests to:
*Dr Anita Chakravarti,
Department of Microbiology, Maulana Azad Medical College, Delhi-110002, India
Article citation: Ashraf A, Chakravarti A,Roy P, Siddiqui O, Goel S, Kapoor N,Kar P. Revisiting the utility of biochemical profile in the diagnosis and management of hepatitis C virus infection: a study from India. J Pharm Biomed Sci 2016;06(09):502–507.
Abstract
Several serum analytes can be used for the management of liver diseases. The present study was carried out to assess the role of biochemical markers in the diagnosis and prognosis of HCV infection. Blood samples (5 ml) collected from 300 patients with chronic HCV infection were analyzed for the presence of HCV antibodies and HBsAg by ELISA, and the infection was reconfirmed using reverse transcription polymerase chain reaction (PCR). Genotyping was done by restriction fragment length polymorphism or direct sequencing. Quantitative detection of HCV RNA by real-time PCR and measurement of Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), Alkaline Phosphatase
(ALP), Bilirubin, Total Protein and Albumin levels was performed before and after 6 months of therapy. Anti HCV antibodies were found in 139 samples, of which 73 were positive for HCV RNA. Genotype 3 was the commonest genotype isolated, while an initial viral load of patients was higher in genotype 1. SGPT, SGOT and bilirubin levels were significantly deranged in HCV antibody positive patients while SGPT, SGOT, albumin and ALP were markedly raised in HCV RNA positive patients. Among 139 HCV AB-positive patients, all six parameters were found to be significantly deranged in HCV RNA positive patients compared to negative patients. Pre-therapy levels of SGPT, bilirubin and ALP were significantly higher than post-therapy levels. SGOT, SGPT and bilirubin are important diagnostic markers of HCV infection, while SGPT, bilirubin and ALP are valuable indicators of response to therapy. Biochemical profile can serve as cost-effective and dependable indirect marker for HCV infection.
KEYWORDS biochemical profile, diagnosis, hepatitis C virus infection, india, prognosis
REFERENCES
1.Penin F, Dubusson J, Rey FA, Moradpour D, Pawlotsky JM.Structural biology of hepatitis C virus. Hepatology. 2004;39(1):5–19.
2.Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology.2013;57(4):1333–1342.
3.Goodgame B, Shaheen NJ, Galanko J, El-Serag HB. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003;98(11):2535–2542.
4.Mukhopadhyaya A. Hepatitis C in India. J Biosci. 2008;33(4):465–73.
5.Chakravarti A, Verma V. Prevalence of Hepatitis C and B viral markers in patients with chronic liver disease: A study of from north India. Indian J Med Microbiol. 2005;23(4):273–274.
6.Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. Natl Med J India. 2006;19(4):203–217.
7.Rehan HS, Manak S, Yadav M, Chopra D, Wardhan N. Diversity of genotype and mode of spread of Hepatitis C virus in Northern India. Saudi J Gastroenterol. 2011;17(4):241–244.
8.Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol.2006;4(5):645–652.
9.Khaliq S, Latief N, Jahan S. Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon- based treatment. Arch Virol. 2014;159(1):1–15.
10. Wolf PL. Biochemical diagnosis of liver disease. Indian J Clin Biochem. 1999;14(1):59–90.
11.Mellor J, Hawkins A, Simmonds P. Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. J Clin Microbiol. 1999;37(8):2525–2532.
12.Chinchai T, Labout J, Noppornpanth S, Theamboonlers A, Haagmans BL, Osterhaus AD, et al. Comparative study of different methods to genotype hepatitis C virus type 6 variants. J Virol Methods.2003;109(2):195–201.
13.Jindal N, Jindal M, Jilani N, Kar P. Seroprevalence of hepatitis C virus (HCV) in health care workers of a tertiary care centre in New Delhi. Indian J Med Res. 2006;123(2):179–180.
14.Verma V, Chakravarti A, Kar P. Genotypic characterization of hepatitis C virus and its significance in patients with chronic liver disease from Northern India. Diagn Microbiol Infect Dis.2008;61(4):408–414.
15.Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol. 2010;36(2):91–133.
16.Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19(7):850–858.
17.Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–567.
18.Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol. 2006;78(4):452–458.
19.Chakravarti A, Dogra G, Verma V, Parkash AS. Distribution pattern of HCV genotypes & its association with viral load. Indian J Med Res. 2011;133(3):326–331.
20.Sarrazin C, Berg T, Lee JH, Rüster B, Kronenberger B, Roth WK, et al. Mutations in the Protein Kinase–Binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a are associated with treatment response. J Infect Dis. 2000;181:432–441.
21.Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
22.Sarasin-Filipowicz M. Interferon therapy of hepatitis C: molecular insights into success and failure. Swiss Med Wkly. 2010;140:3–11.
23.Shakil AO, Conry-Cantilena C, Alter HJ. Volunteer blood donors with antibody to hepatitis C Study Group. Ann Intern Med. 1995;123(5):330–337.
24.Monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy. American Association for the Study of Liver Diseases. 2016. http://www. hcvguidelines.org/full-report/monitoring-patients-who-arestarting-hepatitis-c-treatment- are-treatment-or-have
25.Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type specific differences in geographic origin and disease. Hepatology. 1994;19:13–18.
26.Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different regions of Pakistan and their possible routes of transmission. BMC Infect Dis. 2008;8:69.
27.Interpreting HCV serology and PCR results in diagnostic HCV testing. Australasian Society for HIV Medicine. 2015.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Rampalliwar Sanjeev1,Rajak Chanda1*,Singh Prabhaker2
1Department of Physiology, S. S. Medical College, Rewa, Madhya Pradesh, India
2Department of Pharmacology, S. S. Medical College, Rewa, Madhya Pradesh, India
Address reprint requests to:
*Dr Rajak chanda,
Department of Physiology, S. S. Medical College, Rewa, Madhya Pradesh, 486001, India
Article citation: Sanjeev R, Chanda R,Prabhaker S. Can 6-week practice of Hasya Yoga reduce the cardiovascular hyper-reactivity and other cardiac parameters?. J Pharm Biomed Sci 2016;06(09):508–513.Available at www.jpbms.info
Abstract
Laughter has been used as a therapeutic tool for many years because it is a natural form of medicine. Decades of scientific research had already proven that laughter has a documented
positive impact as a form of complementary preventive and therapeutic medicine.The basic concept with Laughter Yoga is that our body cannot differentiate between real or artificial laughter, hence accords all the benefits of real laughter. The aim of the present study was to investigate whether regular practice of Hasya Yoga for 6 weeks can reduce the cardiovascular hyper-reactivity and other cardiac parameters in healthy young medical students. The study group comprises 40 healthy young medical students of 18–23 years age group. At the start of the study, there were 18 hyper-reactors to cold pressor test. The hyper-reactivity of 13 volunteer (72.22%) converted to hypo reactivity after the Hasya Yoga therapy (combination of laughter and Bhastrika Pranayam) of 6 weeks. Other parameters like basal blood pressure, a rise in blood pressure after cold pressor test, pulse rate, Rate Pressure Product (RPP) and Mean Arterial Pressure (MAP) were also statistically significantly reduced. Regular practice of Hasya Yoga significantly reduces the values of basal blood pressure, cardiovascular hyper-reactivity to blood pressure after one minute of cold stress, heart rate, rate pressure product & MAP after 6 weeks of yoga practice. Laughter is one of our best defenses against stress, and it is important that we find ways to laugh more to cope with stress and remain healthy in the modern world. Laughter Yoga is a perfect way to laugh and get exercise at the same time. Other non-pharmacological methods like meditation, diet, weight reduction and life style modification should also be encouraged to control the modifiable risk factors.
KEYWORDS stress, hasya yoga, bhastrika pranayama, cold pressor test
REFERENCES
1.Li AW, Goldsmith CA. The effects of yoga on anxiety and stress.Altern Med Rev. 2012;17(1):2–35.
2.Julian F, Thayer SS, Yamam JF, Brosschot. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Intl J Cardiol. 2010;141(2):122–131.
3.Cannon WG, De LaPaz D. Emotional stimulation of adrenal secretion. Am J Physiol. 1911;28:64–70.
4.Nagendr HR, Nagaratna R. New perspective in stress management, 3rd Edn. Vivekanand Kendra Yoga Anusandhan Sansthan.1994.
5.Hines EA Jr, Brown GE. A standard stimulus for measuring vasomotor reactions; its application in the study of hypertension. Proc Staff Meet Mayo Clin. 1932;7:332–335.
6.Mourot M, Bouhaddi J, Regnard J. Effects of the cold pressor test on cardiac autonomic control in normal subjects. Physiol Res.2009;58:83–91.
7.Iyengar BKS. Light on yoga: 7th ed. Harpercollins Publishers;New Delhi 2002.
8.Madanmohan, Rai UC, Balavittal V, Thombre DP, Swami Gitananda. Cardiorespiratory changes during savitripranayam and shavasan. The Yoga Review. 1983;3:25–34.
9.Rai UC, Madanmohan, Subramanian N, Swami Gitananda.Oxygen consumption and ventilatory changes during Savitripranayam and Shavasan. J Res Edit Indian Med. 1982;1:23–26.
10.Gopal KS, Anantharaman V, Balachander S, Nishith SD.The cardiorespiratory adjustments in pranayama with and without bandhas in vajrasana. Indian J Med Sci. 1973;27:686–692.
11.Pal GK, Velkumary S, Madanmohan. Effect of short term breathing exercises on the autonomic functions in normal human volunteers.Indian J Med Res. 2004;120:115–121.
12.Mohsen Y, Mojtaba E, Saeid P, FirouzKhaledi. The effect of laughter Yoga on general health among nursing students. Iran J Nurs Midwifery Res. 2014; 19(1):36–40.
13.Chaya MS, Kataria M, Nagendra R. The effects of hearty extended unconditional (HEU) laughter using laughter yoga techniques on physiological, psychological, and immunological parameters in the workplace: a randomized control trial. American Society of Hypertension, Annual Meeting; May 14, 2008; New Orleans, LA.
14.Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M,Morgenstern BZ. Human blood pressure determination by sphygmomanometer. Circulation. 1993;88:2460–2470.
15.Pal GK, Pravati Pal. Text Book of Practical Physiology, 2nd Edition,Orient Longman (India) Pvt. Ltd 2005.
16.Hines EA, Brown GE. Cold pressor test for measuring the reactibility of blood pressure. Am Heart J. 1936;11:1–9
17.Gharote ML. Effect of yogic training on physical fitness. Yoga Mimansa. 1973;15:31–35.
18.Gopal KC, Bhatnagar OP, Subramanian N, Nishith SD. Effect of yogasanas & pranayamas on blood pressure, pulse rate & some respiratory functions. Indian J Physiol Pharmacol.1973;17(3):273–276.
19.Vyas R, Dikshit N. Effect of meditation on respiratory system, cardiovascular system and lipid profile. Indian J Physiol Pharmacol. 2002;46(4):487–491.
20.Udupa K, Madanmohan, Bhavanani AB, Vijayalakshmi P, Krishnamurthy N. Effect of pranayam training on cardiac function in normal young volunteers. Indian J Physiol. Pharmacol.2003;47(1):27–33.
21.Gobel FL, Nordstrom LA, Nelson RR, Jorgensen CR, Wang Y. The rate-pressure-product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris.Circulation. 1978;57:549–556.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
CASE REPORT
Rakhee Modak,Amit Mhapuskar,Darshan Hiremutt,Manjula Hebbale,Shubhangi Gaikwad
Department of Oral Medicine and Radiology, Bharati Vidyapeeth Deemed University Dental College and Hospital,Pune, India
Address reprint requests to:
*Dr Rakhee Modak,
Department of Oral Medicine and Radiology,Bharati Vidyapeeth Deemed University Dental College and Hospital, Pune, India
Article citation: Modak R, Mhapuskar A, Hiremutt D, Hebbale M, Gaikwad S. Arteriovenous malformation of the oral cavity: a case report and review of literature.J Pharm Biomed Sci 2016;06(09):514–517.
Abstract
Arteriovenous malformations (AVMs) are developmental vascular anomalies that occur when the embryonic vascular network fails to differentiate. It is composed of abnormal communications between arteries and veins without a normal intervening capillarybed.
Lymphatic, capillary, venous and AV malformations make up a majority of vascular malformations.
Facial vascular malformations can cause dental emergencies that result in fatal or life threatening and disfiguring situations. Diagnosis of these lesions is essential and management of maxillofacial AVMs remains challenging. In this article, we report a case of intra-oral AV malformation of 16-year-old male patient that was treated with sclerotherapy using 1% sodium tetradecyl sulfate as sclerosant. The treatment was effective,within a short period of time after injection and no recurrence was observed one year postoperatively.
KEYWORDS arteriovenous malformation, vascular malformation, sclerotherapy, developmental anomaly
REFERENCES
1.Kennedy KS. Arteriovenous malformation of the maxilla. Head Neck. 1990;12:512–515.
2.Glowacki J, Mulliken JB. Mast cells in hemangiomas and vascular malformations. Pediatrics. 1982;70:48–51.
3.Kelly DE, Terry BC, Small EW. Arteriovenous malformation of the mandible: report of case. J Oral Surg. 1977;3:387–93.
4.Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg.1983;18:894–99.
5.Burrows PE, Lasjaunias PL, TerBrugge KG, Flodmark O. Urgent and emergent embolization of lesions of the head and neck in children: indications and results. Pediatrics. 1987;80:386–94.
6.Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations.Part 1. J Am Acad Dermatol. 2007;56:353–370.
7.Hayward JR. Central cavernous hemangioma of the mandible: report of four cases. J Oral Surg. 1981;39:526–32.
8.Anderson JH, Grisius RJ, McKean TW. Arteriovenous malformation of the mandible. Oral Surg Oral Med Oral Path. 1981;52:118–125.
9.Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412–22.
10.Kaban LB, Mulliken JB. Vascular anomalies of the maxillofacial region. J Oral Maxillofac Surg. 1986;44:203–13.
11.Spatz S, Kaltman S, Farber S. Vascular malformation: report of a case with eight-year follow up. J Oral Maxillofac Surg. 1985;43:281–84.
12.Kim JY, Kim DI, Do YS, Lee BB, Kim YW, Shin SW, et al. Surgical treatment for congenital arteriovenous malformation: 10 years’ experience. Eur J Vasc Endovasc Surg. 2006;32:101–6.
13.Biller HF, Krespi YP, Sore PM. Combined therapy for vascular lesions of the head and neck with intra-arterial embolization and surgical excision. Otolaryngol Head Neck Surg. 1982;90:37–47.
14. Brooks B. Treatment of traumatic arteriovenous fistula. South Med J.1930;23:100–6 .
15. Macansh JD, Owen MD. Central cavernous hemangioma of the mandible: report of cases. J Oral Surg. 1972;30:293–296.
16. El-Sheikh MM, Zeitdoun IM, El-Massry M, Medra AM. Vascular malformation of the jaw bones: report on nine patients.J Craniomaxillofac Surg. 1993;21:9–14.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Suseela Kumari Pamu*,Lavanya Kollapu
Department of Microbiology, Rangaraya Medical College, GGH Campus Kakinada, Andhrapradesh, India
Address reprint requests to:
*Dr. Suseela Kumari Pamu, Department of Microbiology, Rangaraya Medical College, GGH Campus, Kakinada, Andhrapradesh–533001, India
Article citation: Pamu SK, Kollapu L.Isolation of ß-haemolytic streptococci and grouping by enzymatic extraction.J Pharm Biomed Sci 2016;06(09):518–521.
Abstract
Streptococcus pyogenes (group A streptococcus) is one of the most common and ubiquitous human pathogen. It causes invasive and non-invasive human disease. The group A streptococcus infection can be further complicated by non-suppurative sequelae,
such as rheumatic fever, which usually follows throat infection and glomerulonephritis. A total number of 215 children screened for β-haemolytic streptococci from throat swabs and all culture positives are grouped by enzymatic extraction method and ASO estimation was done. All results were analysed statistically. Out of the 215 throat swabs 22.5% positive for β-haemolytic streptococci and grouped as group A 56.5% group C 31.1% group G 13.4%. All culture positives are sensitive to bacitracin 0.04 units and ASO estimated 54%. The proportion of antibiotic sensitivity was high for penicillin, vancomycin, cefotaxime and erythromycin, and the relative resistance to ampicillin and amoxicillin was seen. Our study suggests that the inappropriate use of antibiotic leads to drug resistance.
KEYWORDS β-haemolytic, streptococcal grouping, ASO, bacitracin sensitivity.
REFERENCES
1.Begovac J. Asymptomatic pharyngeal L carriage of beta-hemolytic streptococcus in J Croatia. Principle and practice of infectious disease. 3rd Edn., Churchill-Livingston Ltd. Philadelphia,1990;15–23.
2.Shet A, Kaplan E. Addressing the burden of group A streptococcal disease in India. Indian J Pediatr. 2004;71:41–48.
3.Carapetis JR. The current evidence for the burden of group A streptococcal diseases. World Health Organization 2005.Available at http://www.who.int/ child-adolescent health / New publications/CHILD_HEALTH/DP/WHO_FCH_CA_05.07pdf.
4.A text book of medical microbiology, Greenwood; Eighteenth edition 2012; part III Chapter 16: page no 187.
5.Menon T, Shanmugasundaram S, Kumar MP, Kumar CP. Group A streptococcal infections of the pharynx in a rural population in south India. Indian J Med Res. 2004;119(suppl):171–173.
6.Rammelkamp CH Jr. Epidemiology of Streptococcal infections.Harvey lect. 1957;51:113-142.
7.Bisno AL. Non-suppurative poststreptococcal sequelae: Rheumatic fever and glomerulonephritis. Vol. 2: Churchill Livingston Ltd. New York. N. Y. 1995.
8.Centor RM, Rvoff GE. Sore throat: streptococcal or not? Pediatr Care 1987;21:28–63.
9.Nandi S, Kumar R, Ray P, Vohra H, Ganguly NK. Group A streptococcal sore throat in a periurban population of Northern India: a one-year prospective study. Bull World Health Organ.2001;79:528–533.
10.Johnson DR, Kalpan E, Sramck J, Bicoava R, Havlicek J, Havalickova H, et al. Laboratory methods for the diagnosis of group A streptococcal infections: World Health Organization, Geneva, Switzerland; 1996.
11.Maxted WR. The use of bacitracin for identifying V J group A haemolytic streptococci. J Clin Pathol. 1953;6:224–226.
12.Levinson ML, Frank PF. Differentiation of group A from other beta hemolytic streptococci with bacitracin. J Bacteriol. 1955;69:284–287.
13.Edrerer GM, Hermann MM, Bruce R, Masten JM, Chapman SS. Rapid extraction method with pronase B for grouping beta hemolytic a streptococci. Appl Microboil. 1972;23:285–288.
14.Coleman DJ, McGhie D, Tebutt GM. Further studies on the reliability of the bacitarcin inhibition test for the presumptive identification of Lancefield Group A streptococci. J Clin Pathol.1977;30:421–426.
15.Pollock HM, Dahlgren BJ. Distribution of streptococcal groups in clinical specimens with evaluation of bacitracin screening. Appl Microbiol. 1974;27:141–143.
16.Waunmaker LW, Ayoub EM. Antibody titers in accute rheumatic fever. Circulation. 1960;21:598–614.
17.Ozturk CE, Yavuz T, Kaya D, Yucel M. The rate of asymptomatic throat carriage of group A streptococcus in school children and associated ASO titers in Duzce, Turkey. Jpn J Infect Dis.2004;57:271–272.
18.Navaneeth BV, Ray N, Chawda S, Selvarani P, Bhaskar M, Suganthi N. Prevelence of beta hemolytic streptococcus carrier rate among schoolchildren in Salem. Indian J Pediatr. 2001;68:985–986.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Zayneb A. Mohammed1*,Haydar F. Al-Tukmagi1,Hassan M. Abbas2
1 Clinical Pharmacy Department, College of Pharmacy, Baghdad University, Baghdad,Iraq
2 Clinical Pharmacy Department, Medical city, Baghdad, Iraq
Address reprint requests to:
*Dr. Zayneb A. Mohammed,
Clinical Pharmacy Department, College of Pharmacy,Baghdad University, Baghdad, Iraq. Tel: (+964) 7718493580
Article citation: Mohammed ZA,Al-Tukmagi HF, Abbas HM. The role of coenzyme Q10 in breast cancer.J Pharm Biomed Sci 2016;06(09):522–525.Available at www.jpbms.info
ABSTRACT
Oxidative stress plays a crucial role in pathogenesis as well as progression of all cancers including breast cancer. The aim of the present study was to explore the possible protective effects of coenzyme Q10, an antioxidant agent, on Doxorubicin induced cardiotoxicity in breast cancer patients, we also investigated the role of coenzyme Q10 on oxidative stress. Sixty-four women having histologically confirmed breast cancer participated in this study. The patients divided into two groups. Group (A) who treated with coenzyme Q10 supplement in addition to chemotherapy adriamycin plus cyclophosphamide (AC). Group (B) treated with chemotherapy only. In this study, serum coenzyme Q10, malondialdehyde (MDA), total antioxidant status (TAS), complete blood count (CBC), serum ALT, AST, creatine kinase (CK), renal functions (serum creatinine and urea), creatine phosphokinase (CPK), high sensitivity C-Reactive protein (hs-CRP) levels were determined. Ejection Fraction (EF) was determined by echocardiography for all participants at baseline as well as post treatment. Statistical analysis was performed using SPSS, version 23, USA for WINDOWS, results are defined as mean ± standard deviation SD. Serum coenzyme Q10, total antioxidant status (TAS) were low at baseline in both groups, serum malondialdehyde (MDA), high sensitivity C-reactive protein (hs-CRP) levels had decreased significantly after supplementation with coenzyme Q10. The reduction in EF was more pronounced in group B at the end of the work. The present study demonstrated that women with breast cancer have a low level of coenzyme Q10 as compared to those of healthy women. It also emphasizes the growing concern that oxidative damage may occur in those patients that exhaust the antioxidant defense of the body leading to a low levels of Coenzyme Q10 and TAS and increasing in inflammatory markers as well as oxidative stress markers which lead to cardiotoxicity. Administration of antioxidant supplements such as a coenzyme Q10 is necessary in women with breast cancer postoperative with adjuvant chemotherapy to minimizes its cardiotoxicity.
KEYWORDS breast cancer, coenzyme Q10, oxidative stress
REFERENCES
1.DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA a Cancer J Clin. 2014;64:52–62.
2.Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer:Epidemiology and Etiology. Cell Biochem Biophys. 2015;72:333–338.
3.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
4.Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther.2010;10:955–960.
5.Beral V, Reeves G, Bull D, Green J. Million Women Study Collaborators. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103:296–305.
6.Thomas S. Cancer As a Metabolic Disease: On The Origin,Management, and Prevention of Cancer. John Wiley & Sons,2012.
7.Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–1642.
8.Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management. Progress in cardiovascular diseases. 2007;49(5):330–52.
9.Gönenç A, Ozkan Y, Torun M, Simşek B. Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J Clin Pharm Ther. 2001;26:141–144.
10.Czarnecka AM, Krawczyk T, Zdrożny M, Lubiński J, Arnold RS,Kukwa W, et al. Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. Breast cancer research and treatment. 2010;121(2):511–8.
11.Halliwell B. Oxidative stress and cancer: have we moved forward? Biochem J. 2007;401:1–11.
12.Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266:37–56.
13.Maria Zowczak-Drabarczyk M, Murawa D, Kaczmarek L, Połom K, Litwiniuk M. Total antioxidant status in plasma of breast cancer patients in relation to ERβ expression. Contemp Oncol (Pozn). 2013;17:499–503.
14.Gönenç A, Erten D, Aslan S, Akinci M, Simşek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int. 2006;30:376–380.
15.Lee BJ, Huang YC, Chen SJ, Lin PT. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition. 2012;28:767–772.
16.Chai W, Cooney RV, Franke AA, Shvetsov YB, Caberto CP,Wilkens LR, et al. Plasma coenzyme Q10 levels and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Epidemiology Biomarkers & Prevention. 2010;19(9):2351–6.
17.Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ,Pella D, et al. Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2012:4;641–649.
18.Niklowitz P, Onur S, Fischer A, Laudes M, Palussen M, Menke F,et al. Coenzyme Q10 serum concentration and redox status in European adults: influence of age, sex, and lipoprotein concentration. J Clin Biochem Nutr. 2016;58:240–245.
19.Anna G, Toru T, Singh RB, Meester D, Wilson F, Douglas W, et al. New roles of coenzyme Q10 in cardiovascular diseases, discovered by a single group. World Heart J. 2013;5:159–171.
20.Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev. 2013;14:243–248.
21.Portakal O, Ozkaya O, Erden Inal M, Bozan B, Koşan M, Sayek I. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clinical Biochem. 2000;33:279–284.
22.Kasapović J, Pejić S, Todorović A, Stojiljković V, Pajović SB. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem Funct. 2008;26:723–730.
23.Shilpa HD, Anita R Bijoor. Malondialdehyde as a marker of lipid peroxidation in acute myocardial infarction patients. MRIMS journal of Health Sciences. 2013;1:20–22.
24.Del Pozo-Cruz J, Rodríguez-Bies E, Navas-Enamorado I, Del Pozo-Cruz B, Navas P, López-Lluch G. Relationship between functional capacity and body mass index with plasma coenzyme Q10 and oxidative damage in community-dwelling elderly people. Exp Gerontol. 2014;52:46–54.
25.Basu S, Harris H, Larsson A, Vasson MP, Wolk A. Is there any role for serum cathepsin S and CRP levels on prognostic information in breast cancer? The Swedish mammography cohort. Antioxid Redox Signal. 2015;23:1298–302.
26.Sara JD, Zhang M, Lennon R, Herrmann J, Lerman L, Lerman A. High sensitivity C-reactive protein is an independent marker of coronary endothelial dysfunction in patients with non obstructive coronary artery disease. J Am Coll Cardiol. 2016;67:360–360
27.Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72:333–338.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work. Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents, and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.